Cellular Senescence as a Mechanistic Driver in Alzheimer’s-Related Neurodegeneration

by Rawamino | Oct 30, 2025 | Peptides

Introduction Aging remains one of the most significant biological risk factors associated with neurodegenerative conditions. Across the lifespan, progressive molecular alterations—ranging from mitochondrial decline to chronic low-grade inflammation—create a cellular...

Targeted α-Synuclein Immunology: UB-312 Peptide Vaccine as a Research Tool for Synucleinopathies

by Rawamino | Oct 30, 2025 | Peptides

Introduction Synucleinopathies such as Parkinson’s disease (PD), dementia with Lewy bodies, and multiple system atrophy are characterized by abnormal aggregation of α-synuclein (αSyn) within neuronal and glial compartments. Mounting evidence suggests that soluble...

A β-Targeting Strategy: V24P(10–40) and Conjugates for Amyloid Sequestration in Alzheimer’s Models

by Rawamino | Oct 29, 2025 | Peptides

Introduction Alzheimer’s disease (AD) remains defined by progressive cognitive decline, synaptic failure, and characteristic proteinopathies that include extracellular amyloid-β (Aβ) deposits and intraneuronal tau aggregates. The “amyloid cascade” framework posits...

Curcumin-PLGA Nanocarriers for Amyloid Pathways, Neuroinflammation, and Adult Neurogenesis in Alzheimer’s Research

by Rawamino | Oct 29, 2025 | Peptides

Introduction Alzheimer’s disease (AD) is marked by network-level cognitive decline emerging from convergent cellular stressors, including proteostasis failure (Aβ and tau misfolding), chronic neuroinflammatory signaling, synaptic dysfunction, and impaired adult...

Investigating the Cdk5i Peptide: Targeting Cdk5/p25 Interactions in Alzheimer’s-Related Neurodegeneration

by Rawamino | Oct 29, 2025 | Peptides

Introduction Biochemical analyses indicated that Cdk5i binds more strongly to the Cdk5/p25 complex than to Cdk5 alone, reflecting its targeted affinity for the pathological form of the kinase. Alzheimer’s disease (AD) represents a complex neurodegenerative disorder...